Table 3.
Notable COVID-19 vaccine candidates in clinical trial.
| Platform | Vaccine | Company | Stage | Location |
|---|---|---|---|---|
| RNA | mRNA 1273 | Moderna | Phase-I (NCT04283461) | USA |
| BNT 162 | Pfizer, BioNTech | Phase-I (NCT04380701) | Germany, USA | |
|
| ||||
| DNA | INO 4800 | Inovio Pharmaceuticals | Phase-I (NCT04336410) | USA |
| Korean Institute of Health | Phase-I | South Korea | ||
|
| ||||
| Lentiviral | LV-SMENP-DC | Shenzhen Genoimmune Medical Institute | Phase-I (NCT04276896) | China |
| aAPC vaccine | Shenzhen Genoimmune Medical Institute | Phase-I (NCT04299724) | China | |
|
| ||||
| Inactivated | PiCoVacc | Sinovac BioTech | Phase-I (NCT04352608) | China |
| COVID-19 vaccine | Wuhan Institute of Biological Products (Sinopharm) | Phase-I | China | |
|
| ||||
| Nonreplicating viral vector | ChAdox1 nCoV-19 | University of Oxford | Phase-I (NCT04324606) | UK |
| Ad5- nCoV | CanSino Biologics | Phase-II (NCT04341389) | China | |
|
| ||||
| Live attenuated | BCG vaccine | Max Planck Institute | Phase-III | Germany |
| BCG vaccine | Radboud University | Phase-III | Netherlands | |
| BCG vaccine | Texas A&M University | Phase-IV | USA | |